Search

Your search keyword '"Capaldo, B."' showing total 17 results
Start Over Author "Capaldo, B." Publisher elsevier bv
17 results on '"Capaldo, B."'

1. Grape pomace polyphenols improve insulin response to a standard meal in healthy individuals: A pilot study

Author

Costabile, G., primary, Vitale, M., additional, Luongo, D., additional, Naviglio, D., additional, Vetrani, C., additional, Ciciola, P., additional, Tura, A., additional, Castello, F., additional, Mena, P., additional, Del Rio, D., additional, Capaldo, B., additional, Rivellese, A.A., additional, Riccardi, G., additional, and Giacco, R., additional

Published
2019
Full Text
View/download PDF

16. Clinical insights into management options for recurrent type 2 diabetes and cardiovascular risk after metabolic-bariatric surgery

Author

Roberta Lupoli, Erminia Lembo, Annalisa Giosuè, Luigi Schiavo, Brunella Capaldo, Lupoli, R., Lembo, E., Giosue, A., Schiavo, L., and Capaldo, B.

Subjects
Blood Glucose, GLP-1 analogue, Nutrition and Dietetics, Endocrinology, Diabetes and Metabolism, Bariatric Surgery, Medicine (miscellaneous), Metabolic-bariatric surgery, Cardiovascular risk, Glucagon-Like Peptide-1 Receptor, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Heart Disease Risk Factors, Risk Factors, Diabetes recurrence, Humans, Hypoglycemic Agents, Cardiology and Cardiovascular Medicine, GLP-1 analogues
Abstract

Aims: Long-term clinical trials evaluating the effects of metabolic-bariatric surgery (MBS) on type 2 diabetes (T2D) demonstrate that a significant proportion of patients either fail to achieve remission or experience T2D recurrence over time. Furthermore, patients with recurrent T2D might require reinstitution of pharmacotherapy to control comorbidities (hypertension, dyslipidemia). This paper reviews therapeutic options in patients with T2D relapse. Data synthesis: Although presently there is no recommended pharmacological strategy, the available data support GLP-1 analogues (GLP-1a) as the most suitable option to control hyperglycemia post-MBS. Beside their efficacy in lowering glycemia and body weight while preserving lean mass, GLP-1a exert cardiovascular/renal-protection and are also safe and well tolerated in surgical patients. In addition, the s.c. route of administration of these medications circumvents the problem of changes in oral drugs bioavailability following MBS. Of note, the available data refers to liraglutide and needs to be confirmed with weekly GLP-1a agents. Information regarding the impact of MBS on the pharmacokinetics of lipid lowering and anti-hypertensive drugs is scarce and inconclusive. The findings indicate that timing from intervention is particularly important because of adaptive intestinal mechanisms. Conclusions: The recurrence of T2D following MBS is a clinically relevant issue. GLP-1a therapy represents the best option to improve glycemic and weight control with good tolerability. Long-term clinical trials will clarify the impact of these drugs on cardiovascular outcomes. A close monitoring of MBS patients is advised to guide drug dosage adjustments and ensure the control of cardiovascular risk factors.

Published
2022

17. Carnitine improves peripheral glucose disposal in non-insulin-dependent diabetic patients

Author

Giuseppina Albano, Brunella Capaldo, Procolo Di Bonito, Raffaele Napoli, Luigi Saccà, Capaldo, B, Napoli, R, Di Bonito, P, Albano, G, and Saccà, L

Subjects
Blood Glucose, Male, medicine.medical_specialty, Time Factors, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Fatty Acids, Nonesterified, Carbohydrate metabolism, Endocrinology, Insulin resistance, Reference Values, Carnitine, Internal medicine, Diabetes mellitus, Internal Medicine, medicine, Humans, Reference Value, Saline, Kinetic, business.industry, Insulin, General Medicine, Metabolism, Middle Aged, medicine.disease, Kinetics, Glucose, Diabetes Mellitus, Type 2, Basal (medicine), Lactates, Lactate, Female, business, Human, medicine.drug
Abstract

To investigate the effects of carnitine on insulin sensitivity in non-insulin-dependent diabetes, insulin-mediated glucose disposal was measured in nine diabetic patients (age 54 +/- 3 years, BMI 27 +/- 1 kg/mq) during a primed (3 mmol) constant (1.7 mumol/min) intravenous infusion of carnitine. In control experiments, the same patients received saline instead of carnitine. Plasma glucose concentration was maintained constant at the level of 100 mg/dl during both studies while plasma insulin was raised to a plateau of 60 microU/ml. Despite similar insulin levels, whole-body glucose utilization was higher with carnitine (4.05 +/- 0.37 mg/kg/min) than saline infusion (3.52 +/- 0.36). Blood lactate concentrations were similar in the basal state and decreased significantly during carnitine infusion (P less than 0.05-0.005), whereas it remained substantially unchanged during saline infusion. Plasma FFA decreased to a similar level (0.1 mmol/l) in both studies. We conclude that an acute carnitine administration is able to improve insulin sensitivity in NIDDM patients. The lactate data suggest that this effect may at least in part be mediated by carnitine activation of pyruvate dehydrogenase.

Published
1991

Catalog

Books, media, physical & digital resources
See catalog results